- CardieX unveils the TicWatch GTH Pro made by global consumer electronics company Mobvoi using technology made by CDX’s subsidiary, ATCOR.
- The smartwatch uses ATCOR’s ‘Arty’ technology to measure central arterial waveforms and detect the hardening of arteries caused by lifestyle factors
- The display data on the accompanying phone app breaks down data collected into five key analysis points that offer insights into a user’s heart and arterial health
- The watch is available on the Mobvoi website and Amazon for US customers, with pre-orders taken for Australian and New Zealand customers
- CDX is down by 2.91 per cent to 50 cents
CardieX (CDX) announced the formal commercial launch of a heart health monitoring smartwatch powered by its subsidiary ATCOR using its heart health technology, made possible through commercial collaboration with Mobvoi.
The TicWatch GTH Pro uses ATCOR’s ‘Arty’ technology to measure central arterial waveforms, which are pressure waves based on the strength of the pulse as blood flows through the body.
The watch is a result of a two-year development partnership between CDX and Mobvoi and was launched on March 1, 2022.
The new smartwatch is able to analyse the hardening of arteries caused by lifestyle factors that could lead to heart disease.
The smartwatch also includes dual PPG sensors, which can track both general and arterial health both from the wrist and by placing your fingertip on the side of the watch.
It will then display data inside of the Mobvoi companion phone app breaking down metrics into five key analysis points which offer insights into their overall heart and arterial health.
“This is the first integration of our market leading SphygmoCor heart health technology into a wearable device and has been the result of a significant two-year collaboration with Mobvoi,” said CDX CEO and Managing Director Craig Cooper.
“Our “Arty Heart Health” platform incorporates unique arterial biometrics and heart health insights based on the 20-year legacy of our ATCOR subsidiary in partnering with global research organizations, pharmaceutical companies, and leading clinical practices.
“It’s this same trusted, clinical grade technology that we are now incorporating into a series of new consumer wearables and home health devices.”
The watch is available for purchase on the Mobvoi website and Amazon in the United States, with both sites taking pre-orders for their Australian and New Zealand customers.
CardieX is down by 2.91 per cent to 50 cents per share at 2:35 pm AEDT.